U.S. pharma huge copyright scrapped two experimental weight loss tablets past 12 months—a as soon as-everyday capsule, lotiglipron, as a result of elevated liver enzymes plus a two times-day-to-day pill, danuglipron, as a result of solid side effects—but CEO Albert Bourla has said the company is determined to “play and win” in the obesity H